Purpose: To assess the prognostic significance of the nuclear receptor binding SET protein 2 (NSD2), a co-activator of the NFkB-pathway, on tumour progression in patients with advanced prostate cancer (PCa).Methods: We retrospectively assessed NSD2 expression in 53 patients with metastatic and castration-resistant PCa. Immunohistochemical staining for NSD2 was carried out on specimen obtained from palliative resection of the prostate. Univariable and multivariable analyses were performed to assess the association between NSD2 expression and PCa progression.Results: Of the 53 patients, 41 had castration-resistant PCa and 48 men had metastases at time of tissue acquisition. NSD2 expression was increased in tumour specimen from 42 patients (79.2%). In univariable Cox regression analyses, NSD2 expression was associated with PSA progression, progression on imaging and overall survival (p = 0.04, respectively). In multivariable analyses, NSD2 expression did not retain its association with these endpoints.Conclusions: NSD2 expression is abnormal in almost 80% of patients with advanced PCa. Expression levels of this epigenetic regulator are easily detected by immunohistochemistry while this biomarker exhibited prognostic value for PCa progression and death in univariable analysis. Further studies on NSD2 involvement in PCa proliferation, progression, metastasis and resistance mechanisms are needed.

中文翻译：

---

肿瘤NSD2表达在晚期前列腺癌中的预后影响。

目的：评估核受体结合SET蛋白2（NSD2）（NFkB途径的共激活物）对晚期前列腺癌（PCa）患者肿瘤进展的预后意义。 53例转移性和去势抵抗性PCa患者。NSD2的免疫组织化学染色是从前列腺姑息切除术获得的标本上进行的。结果：53例患者中，有41例去势抵抗性PCa和48例男性在获得组织时发生转移。42名患者的肿瘤标本中NSD2表达增加（79.2％）。在单变量Cox回归分析中，NSD2表达与PSA进展相关，影像学进展和总体生存率（分别为p = 0.04）。在多变量分析中，NSD2表达未与这些终点保持关联。结论：在近80％的晚期PCa患者中NSD2表达异常。通过免疫组织化学很容易检测到这种表观遗传调控因子的表达水平，而该生物标志物在单变量分析中显示出PCa进展和死亡的预后价值。需要进一步研究NSD2参与PCa增殖，进展，转移和耐药机制。通过免疫组织化学很容易检测到这种表观遗传调节剂的表达水平，而该生物标志物在单变量分析中显示出PCa进展和死亡的预后价值。需要进一步研究NSD2参与PCa增殖，进展，转移和耐药机制。通过免疫组织化学很容易检测到这种表观遗传调控因子的表达水平，而该生物标志物在单变量分析中显示出PCa进展和死亡的预后价值。需要进一步研究NSD2参与PCa增殖，进展，转移和耐药机制。